Search Result

Isoforms Recommended:	CDK12

Results for "

CDK12

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (72) AAK1 (1) Akt (2) Apoptosis (14) ATM/ATR (1) DNA/RNA Synthesis (6) Ephrin Receptor (1) FGFR (1) GSK-3 (1) HDAC (1) HSP (1) IRAK (1) Itk (1) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (3) MAP4K (1) MELK (1) Molecular Glues (11) mTOR (1) p38 MAPK (1) PARP (4) PROTACs (11) RAD51 (1) Raf (2) Reference Standards (2) Small Interfering RNA (siRNA) (3) Target Protein Ligand-Linker Conjugates (1) ULK (1) Wee1 (1)
By Research Areas:	Cancer (71) Inflammation/Immunology (1) Metabolic Disease (3) Neurological Disease (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Recombinant Proteins

Oligonucleotides

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138293

SY-5609 5+ Cited Publications CDK7-IN-3	CDK Apoptosis	Cancer
SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent *CDK7* inhibitor with a K_D of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (K_i=2600 nM), CDK9 (K_i=960 nM), CDK12 (K_i=870 nM). SY-5609 induces apoptosis in tumor cells and has antitumor activity .

HY-80013

THZ1 Maximum Cited Publications 93 Publications Verification	CDK	Cancer
THZ1 is a selective and potent covalent *CDK7* inhibitor with an IC₅₀ of 3.2 nM. THZ1 also inhibits the closely related kinases *CDK12* and *CDK13* and downregulates MYC expression .

HY-101257

YKL-5-124 15+ Cited Publications	CDK	Cancer
YKL-5-124 is a potent, selective, irreversible and covalent *CDK7* inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for *CDK7* and *CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7* than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .

HY-130250

SR-4835 15+ Cited Publications	CDK Apoptosis	Cancer
SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of *CDK12/CDK13* (CDK12: IC₅₀=99 nM, K_d=98 nM; CDK13: K_d=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death .

HY-103618

THZ531 35+ Cited Publications	CDK	Cancer
THZ531 is a selective and covalent inhibitor of both *CDK12* and *CDK13* with IC₅₀s of 158 nM and 69 nM, respectively .

HY-139039

BSJ-4-116 4 Publications Verification	PROTACs CDK	Cancer
BSJ-4-116 is a PROTAC connected by ligands for Cereblon and *CDK. BSJ-4-116 is a highly potent and selective CDK12* degrader (PROTAC) with an IC₅₀ of 6 nM. BSJ-4-116 downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation). BSJ-4-116 exhibits potent antiproliferative effects, alone and in combination with the poly(ADP-ribose) polymerase inhibitor Olaparib (HY-10162) .

HY-10542

GW 5074 5+ Cited Publications	Raf Apoptosis	Cancer
GW 5074 is a potent and selective c-Raf inhibitor with IC₅₀ of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms .

HY-168162

ZLC491	PROTACs CDK	Cancer
ZLC491 is an orally active PROTAC degrader that selectively targets *CDK12/CDK13* and exhibits certain oral bioavailability. ZLC491 induces cereblon- and proteasome-dependent selective degradation of *CDK12* and *CDK13*. ZLC491 inhibits the transcription and expression of long genes, and mainly acts on a subset of DNA damage response genes. ZLC491 inhibits the proliferation of various triple-negative breast cancer cells. ZLC491 can be used in research related to triple-negative breast cancer .

HY-112626

CDK12-IN-2 1 Publications Verification	CDK	Cancer
CDK12-IN-2 is a potent, selective and nanomolar *CDK12* inhibitor (IC₅₀=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 shows excellent kinase selectivity for CDK12 over CDK2, 9, 8, and 7. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12 .

HY-144981

HQ461 1 Publications Verification	CDK Molecular Glues	Cancer
HQ461 is a molecular glue that promotes CDK12-DDB1 interaction to trigger cyclin K degradation. HQ461-mediated degradation of cyclin K impairs CDK12 function, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death .

HY-148065

FMF-06-098-1	PROTACs Wee1 CDK AAK1 ULK MELK Itk IRAK Ephrin Receptor FGFR MAP4K p38 MAPK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .

HY-117203A

CDK12-IN-E9 1 Publications Verification	CDK	Cancer
CDK12-IN-E9 is a potent and selective covalent *CDK12* inhibitor and a non-covalent *CDK9* inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC₅₀> 1 μM .

HY-151110

*PROTAC CDK12/13 Degrader-1*	PROTACs CDK	Cancer
PROTAC CDK12/13 Degrader-1 (7f) is a highly selective cell cycle protein-dependent kinase *CDK12/CDK13* dual degrader with the DC₅₀ values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degrader-1 has anti-proliferative activity and can be used in breast cancer research .

HY-163944

LL-K12-18	DNA/RNA Synthesis Molecular Glues CDK Apoptosis RAD51 ATM/ATR PARP	Cancer
LL-K12-18 is a *CDK12* kinase inhibitor and a dual-site molecular glue. LL-K12-18 inhibits human *CDK12* with an IC₅₀ value of 283.9 nM, and selectively degrades cyclin K via the ubiquitin-proteasome system by stabilizing the *CDK12-DDB1* complex. LL-K12-18 downregulates DNA damage response genes, reduces the phosphorylation level of CTD Ser2 in RNA polymerase II, and modulates biomarkers such as ATM, RAD51, γ-H2AX and cleaved PARP, thereby effectively inducing apoptosis and inhibiting proliferation of breast cancer cells. LL-K12-18 exhibits high target selectivity and serves as a research tool for studies on triple-negative breast cancer .

HY-112261

CDK12-IN-3 1 Publications Verification	CDK	Cancer
CDK12-IN-3 is a potent and selective *CDK12* inhibitor with an IC₅₀ of 491 nM in enzymatic assay.

HY-168555

YJ1206	PROTACs CDK Apoptosis Akt mTOR	Cancer
YJ1206 is an orally active selective *CDK12/CDK13* PROTAC degrader. YJ1206 induces DNA damage and genomic instability, activates the AKT pathway, and triggers apoptosis. YJ1206 reduces tumor cell viability, inhibits tumor growth, and attenuates tumor cell dissemination. YJ1206 is applicable to research related to prostate cancer and high-grade serous tubo-ovarian cancer .

HY-139329

CDK12-IN-6	CDK	Cancer
CDK12-IN-6, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC₅₀ of 1.19 μM at high ATP (2 mM). CDK12-IN-6 has no effect on CDK2/Cyclin E (IC₅₀>20 μM) and CDK9/Cyclin T1 (IC₅₀>20 μM) at high ATP (2 mM) (WO2021116178A1) .

HY-80013A

THZ1 Hydrochloride Maximum Cited Publications 93 Publications Verification	CDK	Cancer
THZ1 Hydrochloride is a selective and potent covalent *CDK7* inhibitor with an IC₅₀ of 3.2 nM. THZ1 Hydrochloride also inhibits the closely related kinases *CDK12* and *CDK13* and downregulates MYC expression .

HY-162706

BSJ-5-63 1 Publications Verification	PROTACs CDK	Cancer
BSJ-5-63 is a potent *CDK12, CDK7, CDK9* PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer (Pink: ligand for target protein (HY-150948); black: linker (HY-W140827); Blue: E3 ligase ligand (HY-112078)) .

HY-144977

dCeMM4	Molecular Glues CDK	Cancer
dCeMM4 (Compound 5) is a molecular glue degrader. dCeMM4 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex .

HY-144971

dCeMM2	Molecular Glues CDK	Cancer
dCeMM2 (Compound 2) is a molecular glue-type degrader that targets cyclin K. dCeMM2 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex .

HY-112462

Cdk1/2 Inhibitor III	CDK	Cancer
Cdk1/2 Inhibitor III (compound 3n) is a highly potent and selective Cdk1/cyclin B and Cdk2/cyclin A inhibitor of with IC₅₀s of 0.6 nM and 0.5 nM, respectively. Cdk1/2 Inhibitor III shows selectivity over VEGF-R2 (IC₅₀ of 32 nM), GSK-3β (IC₅₀ of 140 nM), and a other kinases. Cdk1/2 Inhibitor III inhibits in cell proliferation with IC₅₀s of 20 nM, 35 nM and 92 nM for HCT-116, HeLa, and A375 cells, respectively .

HY-145072

BSJ-01-175	CDK	Cancer
BSJ-01-175 is a potent and selective *CDK12/13* covalent inhibitor. BSJ-01-175 demonstrates exquisite selectivity, potent inhibition of RNA polymerase II phosphorylation, and downregulation of CDK12-targeted genes in cancer cells .

HY-RS02356

CDK12 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
CDK12 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK12 Human Pre-designed siRNA Set A CDK12 Human Pre-designed siRNA Set A

HY-151110A

*PROTAC CDK12/13 Degrader-1 TFA*	PROTACs CDK	Cancer
PROTAC CDK12/13 Degrader-1 (7f) TFA is a highly selective cell cycle protein-dependent kinase *CDK12/CDK13* dual degrader with the DC₅₀ values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degrader-1 TFA has anti-proliferative activity and can be used in breast cancer research .

HY-W181530

NCT02	Molecular Glues CDK Apoptosis Ligands for E3 Ligase	Cancer
NCT02 is a molecular glue degrader based on the E3 ubiquitin ligase DDB1 that targets *CDK12* and its binding partner CCNK. NCT02 triggers the ubiquitination and proteasomal degradation of CCNK, thereby downregulating CDK12 protein levels and inhibiting its downstream signaling pathways. NCT02 can induce tumor cell apoptosis, arrest the cell cycle, and selectively inhibit the proliferation of colorectal cancer cells carrying TP53 defects or belonging to the consensus molecular subtype CMS4. NCT02 has the potential to inhibit tumor growth in in vitro and in vivo models .

HY-139328

CDK12-IN-5	CDK	Cancer
CDK12-IN-5, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC₅₀ of 23.9 nM at high ATP (2 mM). CDK12-IN-5 has no effect on CDK2/Cyclin E (IC₅₀=173 μM) and CDK9/Cyclin T1 (IC₅₀=127 μM) at high ATP (2 mM) (WO2021116178A1) .

HY-144691

PP-C8	PROTACs CDK	Cancer
PP-C8 is a potent and selective *PROTAC CDK12-Cyclin* K** degrader. PP-C8 induces CDK12-Cyclin K degradation with DC₅₀s of 416 and 412 nM for CDK12 and Cyclin K, respectively. PP-C8 demonstrates profound synergistic antiproliferative effects with PARP inhibitor in triple-negative breast cancer (TNBC) .

HY-144976

dCeMM3	Molecular Glues CDK	Cancer
dCeMM3 (Compound 3) is a molecular glue degrader. dCeMM3 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex .

HY-161168

Cyclin K degrader 1	CDK	Cancer
Cyclin K degrader 1 (compound 40) is an AT7519 (HY-50940) based Cyclin K degrader with DC₅₀ of 21 nM. Cyclin K degrader 1 has an affinity for cyclin K that is ~500-fold higher than its affinity for CDK12 .

HY-153244

MFH290 1 Publications Verification	CDK	Cancer
MFH290 is a potent and highly selective cyclin-dependent kinase 12/13 (CDK12/13) covalent inhibitor. MFH290 forms a covalent bond with Cys-1039 of CDK12 and exhibits excellent kinome selectivity and inhibits the phosphorylation of serine-2 in the C-terminal domain (CTD) of RNA-polymerase II (Pol II). MFH290 is used for cancer research .

HY-46568

CDK7/12-IN-1	CDK	Cancer
CDK7/12-IN-1 is a selective *CDK7/12* inhibitor with IC₅₀s of 3 and 277 nM for CDK7 and CDK 12, respectively. CDK7 and CDK12 inhibition is an effective strategy to inhibit tumour growth .

HY-101257B

YKL-5-124 TFA 15+ Cited Publications	CDK	Cancer
YKL-5-124 TFA is a potent, selective, irreversible and covalent *CDK7* inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for *CDK7* and *CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7* than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .

HY-177786

CDK12 ligand-3	Molecular Glues CDK	Cancer
CDK12 ligand-3 is a molecular glucose degrading agent that targets the *CDK12* protein (DC₅₀ = 35 nM). CDK12 ligand-3 degrades CDK12, CDK13 and their regulatory subunit Cyclin K in a concentration dependent manner, and inhibits RNA polymerase II CTD (Ser2) phosphorylation. CDK12 ligand-3 exhibits potent anti proliferative activity against Jurkat cells. CDK12 ligand-3 can be used for research on cancers such as leukemia .

HY-173059

CDK12/13-IN-3	CDK	Cancer
CDK12/13-IN-3 (Compound 12b) is the orally active inhibitor for *CDK* that inhibits *CDK12* and *CDK13* with IC₅₀ of 107.4 nM and 79.4 nM. CDK12/13-IN-3 inhibits the phosphorylation of Ser2 on the CTD of RNA polymerase II, induces DNA damage, and downregulates the gene expression of DNA damage response (DDR). CDK12/13-IN-3 exhibits antiproliferative activity against multiple cancer cells with IC₅₀ of nanomolar levels. CDK12/13-IN-3 exhibits antitumor effect in mouse models, exhibits good pharmacokinetic properties with an oral bioavailability of 53.6% .

HY-116871

YKL-1-116	CDK	Cancer
YKL-1-116 is a selective and covalent inhibitor of *Cdk7. YKL-1-116 does not target Cdk9, Cdk12, or Cdk13. YKL-1-116 is more potent than THZ1 (HY-80013) toward both Cdk7 ^WT and Cdk7 ^as, although Cdk*7 ^as is relatively resistant to this compound as well .

HY-179289

ZLY025	Molecular Glues CDK Apoptosis	Cancer
ZLY025 is a potent and orally active CCNK molecular glue degrader with an DC₅₀ of 42.7 nM. ZLY025 exhibits broad-spectrum antiproliferative activity against various tumor cells with IC₅₀ values ranging from 0.08 to 2.45 μM. ZLY025 can induce cells apoptosis and G1 phase arrest. ZLY025 can be used for the research of cancer, such as lung cancer .

HY-168556

YJ9069	CDK PROTACs DNA/RNA Synthesis	Cancer
YJ9069 is a selective CDK12/CDK13 PROTAC degrader with an IC₅₀ of 22.22 nM for in VCaP cells. CDK12/13 degradation rapidly triggers gene-length-dependent transcriptional elongation defects, leading to DNA damage and cell-cycle arrest. YJ9069 effectively inhibits proliferation in subsets of prostate cancer cells and significantly suppresses prostate tumor growth. (Pink: CDK12/CDK13 degradation agent (HY-168658); Black: Linker (HY-W015967); Blue: ligand for E3 ligase (HY-103596)) .

HY-171787A

PPA-037 TFA	CDK	Cancer
PPA-037 TFA is an orally active, highly potent and selective inhibitor of cyclin-dependent kinase 12 (CDK12). PPA-037 TFA induces the degradation of cyclin K (Cyclin K), enhancing antiproliferative effects on tumor cells. PPA-037 TFA is promising for research of cancers .

HY-172224

*PARP1/CDK12-IN-1*	CDK PARP	Cancer
PARP1/CDK12-IN-1 (107) is a dual inhibitor of *CDK12* and PARP1, with IC₅₀ values of 285 nM and 34 nM for CDK12 and PARP1, respectively .

HY-E70658

CDK12 R722C/CycK Recombinant Human Active Protein Kinase	CDK	Cancer
CDK12 R722C/CycK Recombinant Human Active Protein Kinase is a cyclin-dependent kinase and regulates the expression of genes involved in DNA repair and is required for the maintenance of genomic stability .

HY-176279

Hsp90-IN-42	HSP	Cancer
Hsp90-IN-42 (Compound 13l) is a potent heat shock protein 90 (Hsp90) inhibitor (IC₅₀=15.65 nM). Hsp90-IN-42 reduces the stability of the epidermal growth factor receptor (EGFR), suppressing the activation of the EGFR-Akt signaling pathway, inducing G0/G1 phase arrest in colorectal cancer cells (such as HT-29 cells), and slightly triggering apoptosis. Hsp90-IN-42 also inhibits cell proliferation and migration by down-regulating the expression of CDK12, CDK13, and Bcl-2 proteins, and up-regulating the expression of Bax protein. Hsp90-IN-42 is promising for research of colorectal cancer .

HY-149819

CDK/HDAC-IN-3	HDAC CDK	Cancer
CDK/HDAC-IN-3 is an orally active HDACs/CDKs dual inhibitor. CDK/HDAC-IN-3 has potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2 and HDAC3 with IC₅₀ values of 98.32 nM, 98.85 nM, 100 nM, 62.12 nM, 93.28nM and 82.87 nM. CDK/HDAC-IN-3 can be used for the acute myeloid leukemia (AML) .

HY-172970

HQY1428	CDK DNA/RNA Synthesis Apoptosis	Cancer
HQY1428 is an orally active CDK12 inhibitor. HQY1428 inhibits DNA replication, causes G2/M arrest in SKOV3 cells, induces DNA double-strand breaks and apoptosis. HQY1428 has anti-tumor activity in the SKOV3 xenograft mouse model. HQY1428 combined with the HER2 inhibitor Lapatinib (HY-50898) in the NCI-N87 xenograft mouse model produces a synergistic therapeutic effect .

HY-171786

CDK12-IN-8	CDK	Cancer
CDK12-IN-8 (Compound Cpd143) is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). CDK12-IN-8 inhibits CDK12-mediated phosphorylation of the C-terminal domain (CTD) serine 2 of RNA polymerase II, interfering with gene transcription elongation and DNA damage repair pathways. CDK12-IN-8 is promising for research of cancers with high CDK12 expression such as small cell lung cancer and triple-negative breast cancer .

HY-162528

CDK12-IN-7	CDK	Cancer
CDK12-IN-7 (Compound 2) is a *CDK12* and *CDK2* inhibitor with IC₅₀ values of 42 and 196 nM, respectively. CDK12-IN-7 has anti-cell proliferation activity and can be used in cancer research .

HY-157297

CDK-IN-13	CDK	Cancer
CDK-IN-13 (compound 32E) is a potent and selective inhibitor of *CDK12/cyclinK* with an IC₅₀ of 3 nM. CDK-IN-13 inhibits the growth of the HER2-positive breast cancer cell lines .

HY-RS02358

Cdk12 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk12 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk12 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk12 Rat Pre-designed siRNA Set A Cdk12 Rat Pre-designed siRNA Set A

HY-RS02357

Cdk12 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk12 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk12 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk12 Mouse Pre-designed siRNA Set A Cdk12 Mouse Pre-designed siRNA Set A

HY-150641

CDK-IN-9	CDK Apoptosis DNA/RNA Synthesis Molecular Glues	Cancer
CDK-IN-9 (compound 24) is a potent *CDK* inhibitor, also as a molecular glue inducing an interaction between CDK12 and DDB1, with an IC₅₀ values of 4 nM for CDK2/E. CDK-IN-9 leads to polyubiquitination of cyclin K and its subsequent degradation. CDK-IN-9 induce apoptosis through dephosphorylation of retinoblastoma protein and RNA polymerase II .

Species:	Human (5)
Tag:	His (1) Tag Free (1) GST (4) Flag (2)
Source:	Sf9 insect cells (5)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701360

	CDK12-CCNK Heterodimer Protein, Human (sf9) CDK12; CCNK; Cyclin-dependent kinase 12; Cdc2-related kinase; arginine/serine-rich; CrkRS; Cell division cycle 2-related protein kinase 7; CDC2-related protein kinase 7; Cell division protein kinase 12; hCDK12; Cyclin-K	Human	Sf9 insect cells
	The CDK12 protein is a cyclin-dependent kinase that critically phosphorylates the C-terminal domain of POLR2A, thereby regulating transcription elongation. It selectively targets "Ser-5" phosphorylated at "Ser-7" in the CTD repeat and can also target "Ser-2". CDK12-CCNK Heterodimer Protein, Human (sf9) is a recombinant protein dimer complex containing human-derived CDK12-CCNK Heterodimer protein, expressed by sf9 insect cells , with tag free.

HY-P702692

	CDK12-CCNT1 Protein, Human (Active, sf9, GST, Flag, His) CDK12; CCNK; Cyclin-dependent kinase 12; Cdc2-related kinase; arginine/serine-rich; CrkRS; Cell division cycle 2-related protein kinase 7; CDC2-related protein kinase 7; Cell division protein kinase 12; hCDK12; Cyclin-K	Human	Sf9 insect cells
	The CDK12 protein is a cyclin-dependent kinase that critically phosphorylates the C-terminal domain of POLR2A, thereby regulating transcription elongation. It selectively targets "Ser-5" phosphorylated at "Ser-7" in the CTD repeat and can also target "Ser-2". CDK12-CCNT1 Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK12-CCNT1, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

HY-P701361

	CDK12-CCNK Heterodimer Protein, Human (Active, sf9, GST, FLAG) CDK12; CCNK; Cyclin-dependent kinase 12; Cdc2-related kinase; arginine/serine-rich; CrkRS; Cell division cycle 2-related protein kinase 7; CDC2-related protein kinase 7; Cell division protein kinase 12; hCDK12; Cyclin-K	Human	Sf9 insect cells
	The CDK12 protein is a cyclin-dependent kinase that critically phosphorylates the C-terminal domain of POLR2A, thereby regulating transcription elongation. It selectively targets "Ser-5" phosphorylated at "Ser-7" in the CTD repeat and can also target "Ser-2". CDK12-CCNK Heterodimer Protein, Human (sf9, GST, FLAG) is a recombinant protein dimer complex containing human-derived CDK12-CCNK Heterodimer protein, expressed by sf9 insect cells , with N-Flag, N-GST labeled tag.

HY-P702886

	CDK12-CCNK Heterodimer Protein, Human (Active, sf9, GST) CRK7; CRKRS; KIAA0904	Human	Sf9 insect cells
	The CDK12 protein is a cyclin-dependent kinase that critically phosphorylates the C-terminal domain of POLR2A, thereby regulating transcription elongation. It selectively targets "Ser-5" phosphorylated at "Ser-7" in the CTD repeat and can also target "Ser-2". CDK12-CCNK Heterodimer Protein, Human (sf9, GST) is the recombinant human-derived CDK12-CCNK, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P702885

	CDK12-CCNK Heterodimer Protein, Human (Active, 658-1490, sf9, GST) CRK7; CRKRS; KIAA0904	Human	Sf9 insect cells
	The CDK12 protein is a cyclin-dependent kinase that critically phosphorylates the C-terminal domain of POLR2A, thereby regulating transcription elongation. It selectively targets "Ser-5" phosphorylated at "Ser-7" in the CTD repeat and can also target "Ser-2". CDK12-CCNK Heterodimer Protein, Human (658-1490, sf9, GST) is the recombinant human-derived CDK12-CCNK, expressed by Sf9 insect cells, with N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: